A novel long non-coding RNA-PRLB acts as a tumor promoter through regulating miR-4766-5p/SIRT1 axis in breast cancer

Yiran Liang1, Xiaojin Song1, Yaming Li1, Yuting Sang1, Ning Zhang1, Hanwen Zhang1, Ying Liu1, Yi Duan1, Bing Chen2, Renbo Guo3, Wenjing Zhao2, Lijuan Wang2 and Qifeng Yang1

Abstract

Accumulating evidence indicates that long non-coding RNAs (lncRNAs) play a critical role in cancerous processes as either oncogenes or tumor suppressor genes. Here, we demonstrated that lncRNA-PRLB (progression-associated lncRNA in breast cancer) was upregulated in human breast cancer tissues and breast cancer cell lines. Further evaluation verified that lncRNA-PRLB was positively correlated with the extent of metastasis, and its expression was correlated with shorter survival time of breast cancer patients. We identified microRNA miR-4766-5p as an inhibitory target of lncRNA-PRLB. Both lncRNA-PRLB overexpression and miR-4766-5p knockdown could remarkably enhance cell growth, metastasis, and chemoresistance. We also determined that sirtuin 1 (SIRT1) was an inhibitory target of miR-4766-5p, and that SIRT1 was inhibited by both lncRNA-PRLB knockdown and miR-4766-5p overexpression. Significantly, we found that the promotion of cell proliferation and metastasis, the acquisition of chemoresistance, and the increased expression of SIRT1 induced by lncRNA-PRLB overexpression could be partly abrogated by ectopic expression of miR-4766-5p. Taken together, our findings indicated that lncRNA could regulate the progression and chemoresistance of breast cancer via modulating the expression levels of miR-4766-5p and SIRT1, which may have a pivotal role in breast cancer treatment and prognosis prediction.

Introduction

Breast cancer is one of the most common malignancy among women and the incidence increases gradually in the world1. Although the combination of surgery and adjuvant therapy can effectively improve the prognosis of patients with breast cancer, the occurrence of metastasis and chemoresistance could lead to disease recurrence and cancer-associated mortality2, 3. The development of breast cancer is a complicated process involving accumulation of both genetic and epigenetic changes. Therefore, further study of the precise molecular mechanisms involved in the progression and chemoresistance is essential for the reduction of mortality and easing the burden caused by breast cancer.

Recently, emerging evidence suggested that long non-coding RNAs (lncRNAs) played essential roles in human diseases, especially in tumors4, 5. LncRNAs are defined as a class of non-coding RNAs (ncRNAs) that are longer than 200 nucleotides6. Although lncRNAs lack cross-species conservation7, 8, increasing evidence suggests that lncRNAs play important roles in a variety of cellular process, and therefore may contribute to tumor initiation, metastasis, and chemoresistance9–12. LncRNA HOTAIR, which is one of the most famous lncRNAs, played significant role in lung cancer13, renal cancer14, esophageal cancer15, ovarian cancer16, and so on. LncRNA-MALAT1 promoted lung cancer metastasis and could serve as a treatment target17. Linc00152 was overexpressed in breast...
cancer and participated in regulating cell proliferation. LncRNA CRNDE was originally found to be increased in colorectal cancer and could promote cell proliferation, metastasis, and chemoresistance. However, although a few lncRNAs have been reported, more studies were needed to clarify the regulation mechanism of lncRNAs in breast cancer.

Emerging evidences suggest that lncRNA may function as a competing endogenous RNA (ceRNA) in modulating the expression and biological functions of microRNA. In the present study, we identified a novel lncRNA-PRLB (progression-associated lncRNA in breast cancer) as a tumor promoter in breast cancer. Furthermore, lncRNA-PRLB was associated with breast cancer progression and chemoresistance by regulating the expression of miR-4766-5p. Our findings suggested that the inhibition of lncRNA-PRLB represented a promising therapeutic strategy for breast cancer treatment.

**Results**

**LncRNA-PRLB is upregulated in breast cancer and is associated with advanced tumor stage and poor prognosis**

To identify lncRNAs involved in breast cancer, we performed an lncRNA microarray analysis in a set of pretreated tumor tissues from a cohort of breast cancer patients who presented with good or poor responses to chemotherapy. Using a >1.5-fold change and a $P$ value of <0.05 as a cutoff point, we found that there were 238 lncRNAs with significantly different expression profile (Supplementary Table 1). The top 10 upregulated and downregulated lncRNAs are shown in Supplementary Figure S1a. In order to investigate the relevance of these lncRNAs in breast cancer development, we first sought to determine their expression levels from TCGA database. As shown in Supplementary Figure S1b, lncRNA ENST00000521030 expression level was upregulated in breast cancer tissues. In order to specify the function of lncRNA-PRLB, we evaluated the expression levels of lncRNA-PRLB and other four unregulated lncRNAs in 18 breast cancer tissues compared with their normal counterparts and breast cancer cells compared with normal breast cells, and found that the differential expression of lncRNA-PRLB was most significant (Fig. 1a, b and Supplementary Figure S1c, d). Therefore, we chose this uncharacterized lncRNA to be a potential candidate to further investigate its role in the progression of breast cancer and named it lncRNA-PRLB. LncRNA-PRLB is located on 8p11.21 in humans and is composed of three exons and has a full length of 663 nt (Supplementary Figure S1e). We then analyzed the coding potential of
Fig. 2 (See legend on next page.)
LncRNA-PRLB. The open reading frame finder of the National Center for Biotechnology Information and conserved domain database failed to predict a protein of more than 55 amino acids based on the lncRNA-PRLB sequence (Supplementary Figure S1f)\textsuperscript{25}. In addition, lncRNA-PRLB does not contain a valid Kozak consensus sequence, which further supported the notion that the lncRNA-PRLB has no protein-coding potential. The secondary structure of lncRNA-PRLB is shown in Supplementary Figure S1g. We then analyzed the association between lncRNA-PRLB expression and the clinicopathological features, and they are summarized in Supplementary Table 2. Higher level of lncRNA-PRLB was identified in the primary tumor tissue from patients who developed metastasis (Fig. 1c). Furthermore, Kaplan–Meier survival analysis showed that patients with high lncRNA-PRLB expression levels exhibited poor overall survival and disease-free survival (Fig. 1d and Supplementary Figure S1h). Moreover, high lncRNA-PRLB expressions in tumors and lymph node metastasis had significantly higher risk of death (Supplementary Table 3). Multivariate analysis showed major effects of lncRNA-PRLB overexpression on the patients' prognosis (Supplementary Table 4). These findings further demonstrated that lncRNA-PRLB may play an important role in the regulation of breast cancer development, and it may serve as a prognostic marker in breast cancer.

**LncRNA-PRLB promotes breast cancer cell proliferation and metastasis in vitro**

We next sought to explore the biological and functional significance of lncRNA-PRLB. The real-time quantitative reverse transcription-PCR (qRT-PCR) analysis was used to detect the transfection efficiency (Fig. 2a). 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assays revealed suppressed proliferation in lncRNA-PRLB-downregulated cells (Fig. 2b). Flow cytometry showed that lncRNA-PRLB knockdown increased the G1-phase population, and decreased the S-phase population in three breast cancer cells (Fig. 2c). Compared with negative controls, lncRNA-PRLB downregulation resulted in increased apoptosis in breast cancer cells (Fig. 2d). It was also comparable with the results of terminal-deoxynucleotidyl transferase-mediated nick end labeling (TUNEL) assays (Fig. 2e). Meanwhile, cell migration/invasion assay revealed an inhibited effect on metastasis in cells transfected with si-PRLB (Fig. 2f). Considering the significant role of epithelial–mesenchymal transition (EMT) in cancer cell malignant transformation, we further evaluated the effect of lncRNA-PRLB in EMT. Western blot (WB) showed that lncRNA-PRLB knockdown increased the levels of epithelial markers (E-cadherin) and decreased the levels of mesenchymal markers (N-cadherin, vimentin, and fibronectin) (Fig. 2g). LncRNA-PRLB overexpression could also significantly enhance the proliferation and invasive capacity of breast cancer cells (Supplementary Figure 2). Our findings support the view that lncRNA-PRLB knockdown could inhibit proliferation and invasion in breast cancer cells.

**LncRNA-PRLB is required for 5-FU tolerance of breast cancer cells**

Considering the relevance between high metastatic ability of breast cancer cells and the arising of chemoresistance, we further investigated the role of lncRNA-PRLB in 5-fluorouracil (5-FU) resistance. We first evaluated the half-maximal inhibitory concentration (IC\textsubscript{50}) of 5-FU in different breast cancer cells, and MDA-MB-231 showed the lowest resistance to 5-FU (Fig. 3a). Consistently, the expression of lncRNA-PRLB was significantly lower in MDA-MB-231 than other breast cancer cells (Fig. 1c). Thus, we further established 5-FU-resistant cell lines (MDA-MB-231/5-FU). The IC\textsubscript{50} of 5-FU and lncRNA-PRLB expression in MDA-MB-231/5-FU cells was significantly higher compared with the parental cell lines (Fig. 3b). We suppressed lncRNA-PRLB in MDA-MB-231/5-FU cells (Fig. 3c), and silencing lncRNA-PRLB resensitized breast cancer cells to 5-FU treatment (Fig. 3d). Consistently, lncRNA-PRLB knockdown suppressed cell proliferation (Fig. 3e) and enhanced the 5-FU-induced cell apoptosis, as determined by levels of cleaved-caspase-8 and caspase-3 expressions, as well as flow cytometry (Fig. 3f, g). We further evaluated the effect of

(see figure on previous page)

**Fig. 2 LncRNA-PRLB knockdown inhibited cell proliferation and metastasis in vitro.** a The knockdown of lncRNA-PRLB in MDA-MB-231, MDA-MB-468, and MCF7 cells was validated with qRT-PCR. b Effects of lncRNA-PRLB knockdown on the proliferation of MDA-MB-231, MDA-MB-468, and MCF7 cells were examined with MTT assay. Experiments were performed in triplicate. c Flow cytometry was performed to determine the effect of lncRNA-PRLB on changes of cell cycle distribution. The data represent the mean ± SD from three independent experiments. d The percentage of apoptotic cells was determined by flow cytometric analysis. The data represent the mean ± SD from three independent experiments. e Representative TUNEL staining (red fluorescence) of MDA-MB-468 cells transfected with si-PRLB. Columns are the average of three independent experiments. f Transwell migration and invasion assays were used to evaluate MDA-MB-231 and MDA-MB-468 cell numbers with or without lncRNA-PRLB downregulation. Columns are the average of three independent experiments. g EMT-related markers were detected by Western blot in MDA-MB-231 cells lines with and without lncRNA-PRLB downregulation. *P < 0.05, **P < 0.01, and ***P < 0.001, Student’s t test; NS nonsignificant.
Fig. 3 (See legend on next page.)
LncRNA-PRLB in EMT. MDA-MB-231/5-FU cells presented a fibroblast-like morphology, which is typical of the mesenchymal phenotype of cells compared with the corresponding parental cells (Fig. 3h). Transwell assay revealed that LncRNA-PRLB knockdown inhibited the cell migration ability (Fig. 3i), increased expression of epithelial markers (E-cadherin), and decreased the expression of mesenchymal markers (N-cadherin, vimentin, and fibronectin) (Fig. 3). Consistently, LncRNA-PRLB overexpression endowed breast cancer cells with refractoriness to 5-FU (Supplementary Figure 3). Consequently, these results indicated that LncRNA-PRLB is required for 5-FU tolerance of breast cancer cells, while enhancing their proliferation and metastasis.

LncRNA-PRLB abundantly sponges miR-4766-5p and miR-4766-5p promotes cell proliferation, metastasis, and chemoresistance in breast cancer

Many lncRNAs are known to function as a ceRNA to modulate the expression and biological functions of microRNA (miRNA). The subcellular distribution assay revealed that LncRNA-PRLB is predominately located in the plasma (Fig. 4a). The potential targets of LncRNA-PRLB were predicted by the bioinformatics databases (RegRNA); we identified that miR-4766-5p-binding sites were present in LncRNA-PRLB and the expression level of miR-4766-5p correlated negatively with that of LncRNA-PRLB (Fig. 4b and Supplementary Figure S4a). To further explore the underlying mechanism of the LncRNA/miRNA regulatory function, dual-luciferase reporter assay was performed. MiR-4766-5p mimics reduced the luciferase activity of wild-type LncRNA-PRLB reporter vector, but not that of mutant reporter vector (Fig. 4c). RNA-binding protein immunoprecipitation (RIP) assay was performed to determine whether LncRNA-PRLB and miR-4766-5p are in the same RNA-induced silencing complex. The level of LncRNA-PRLB and miR-4766-5p was higher in anti-Ago2 group than that in the anti-normal IgG group (Fig. 4d). Importantly, miR-4766-5p overexpression caused opposite changes in the expression levels of LncRNA-PRLB (Supplementary Figure S4b), indicating that there exists mutual regulation between miR-4766-5p and LncRNA-PRLB. Taken together, the results indicated that miR-4766-5p was an inhibitory target of LncRNA-PRLB.

To determine the biological function of miR-4766-5p, qRT-PCR was first applied to detect miR-4766-5p expression efficiency (Fig. 4e and Supplementary Figure S4c). Decreased expression of miR-4766-5p was observed in MDA-MB-231/5-FU cells compared with parental cells (Fig. 4f), and miR-4766-5p mimics could inhibit viability, promote apoptosis, inhibit migration, and decrease 5-FU resistance in breast cancer cells (Fig. 4f–h and Supplementary Figure S4d–h). Rescue experiments showed that miR-4766-5p mimics could attenuate the proliferation, migration, and chemoresistance promotion of breast cancer cells induced by LncRNA-PRLB (Fig. 5a–e). The above results suggested that miR-4766-5p negatively regulated proliferation, EMT, and 5-FU resistance and breast cancer cells, thereby impaired the function of LncRNA-PRLB.

miR-4766-5p targets SIRT1 and regulates its expression

Using the bioinformatics algorithms TargetScan, we identified that miR-4766-5p potentially targeted SIRT1. Dual-luciferase reporter assays found that miR-4766-5p mimics led to the attenuation of fluorescence of the wild-type 3′-untranslated region (WT 3′-UTR), but had no effect on the mutant (MUT) 3′-UTR of SIRT1 (Fig. 6a, b). Furthermore, the protein levels of SIRT1 protein and RNA in breast cancer cells were reduced by miR-4766-5p overexpression (Fig. 6c, d and Supplementary Figure S5a, b). These results indicate that SIRT1 is a direct target of miR-4766-5p.

LncRNA-PRLB promotes proliferation, metastasis, and chemoresistance partly by regulating SIRT1 expression through protecting it from miR-4766-5p-mediated degradation

To clarify the role of SIRT1 in breast cancer cells, we perturbed SIRT1 levels in breast cancer cells. The efficiency of SIRT1 knockdowns were confirmed by...
Fig. 4 (See legend on next page.)
We also determined whether lncRNA-PRLB resistant cell lines compared with the parental cell lines increased expression of SIRT1 was observed in 5-FU–mediated regulation of SIRT1 signaling.

Collectively, these data strongly support the hypothesis that lncRNA-PRLB promotes breast cancer cell proliferation and chemoresistance via miR-4766-5p-mediated regulation of SIRT1 signaling.

**LncRNA-PRLB promotes breast cancer cell proliferation, metastasis, and chemoresistance in vivo**

We then used a nude mouse xenograft model to further investigate the oncogenic role of lncRNA-PRLB in vivo. MDA-MB-231 cells stably transfected with shPRLB or control were subcutaneously injected into mice. The shPRLB group treated with phosphate-buffered saline (PBS) or 5-FU showed significantly reduced tumor growth and tumor weight compared with the controls (Fig. 7a–c). Moreover, combined treatment with lncRNA-PRLB knockdown and 5-FU led to an even further reduction in tumor volume and tumor weight (Fig. 7a–c). Consistently, lncRNA-PRLB and SIRT1 expression were lower, while miR-4766-5p expression was higher in tumor tissues derived from the shPRLB group than those from controls (Supplementary Figure S7a). Moreover, the hematoxylin and eosin (H&E) staining and immunohistochemistry assay results showed that the tumors developed from shPRLB cells displayed alterations in shape and reduced Ki-67 and SIRT1 staining compared with tumors formed from empty vector-transfected cells (Fig. 7d).

To further evaluate the effect of lncRNA-PRLB on tumor metastasis in vivo, MDA-MB-231 cells with stable lncRNA-PRLB overexpression and control cells were injected into nude mice through the tail vein. H&E staining was performed to evaluate tissue morphology (Fig. 7e). All six mice transplanted with MDA-MB-231 lncRNA-PRLB cells had small pulmonary metastatic nodules, while only two out of six mice in the control group ended up with lung metastasis. Moreover, both the volume and number of lung metastatic nodules were increased in lncRNA-PRLB overexpression groups compared with control groups (Fig. 7e, f). Our findings indicate that lncRNA-PRLB had an important role in breast cancer tumor development and chemoresistance in vivo.

**Discussion**

Accumulating studies have reported that IncRNAs are dysregulated in many types of human cancers, including breast cancer, bladder cancer, prostate cancer, colorectal cancer, ovarian cancer, osteosarcoma, and so on, providing novel therapeutic opportunities to treat cancer. Considering the abundance and functionality of IncRNAs, it is worthwhile to systematically explore the function of those uncharacterized RNA transcripts, which may help exploit new promising therapeutic strategy for the treatment of breast cancer.

Our studies revealed that lncRNA-PRLB, a novel IncRNA located in chromosome 8, played essential role in...
Fig. 5 (See legend on next page.)
breast cancer progression and chemoresistance. LncRNA-PRLB was significantly upregulated in breast cancer cell lines and breast cancer tissues. High IncRNA-PRLB expression was associated with worse prognosis, and IncRNA-PRLB expression was an independent prognostic factor for breast cancer patients. However, we failed to evaluate the influence of metastasis on overall survival in multivariate analysis, possibly due to the shorter follow-up time and smaller size of the cohort. Then, we further explore the functional role of IncRNA-PRLB in breast cancer. Our data indicated that knockdown of IncRNA-PRLB inhibited and overexpression of it promoted breast cancer cell proliferation, metastasis, chemoresistance, and tumor growth both in vitro and vivo, suggesting that IncRNA-PRLB functions as an oncogene. Accumulating evidence suggested that tumor metastasis and chemoresistance might be closely associated to biological events, which are two major inseparable causes of cancer-related lethality. Our results demonstrated that IncRNA-PRLB knockdown could significantly inhibit the migration and invasion ability in both MDA-MB-231/5-FU and parental cells, preliminarily revealing the relevance between metastasis and chemoresistance. In response to chemotherapy, cell apoptosis was one of the most commonly activated pathway, and disruption of apoptosis would facilitate multidrug resistance. 5-FU is a pyrimidine analog, which works through irreversible inhibition of thymidylate synthase and results in apoptosis of cancer cells. In this manuscript, we showed that IncRNA-PRLB knockdown could significantly increase apoptosis after 5-FU treatment, and IncRNA-PRLB alone also showed a slight effect on the apoptosis pathway, indicating that IncRNA-PRLB knockdown could enhance the susceptibility of breast cancer cells to 5-FU via increasing 5-FU-induced apoptosis. Although there was a significant effect of IncRNA-PRLB on 5-FU resistance, investigation on more types of chemotherapy was needed to enhance the significance of IncRNA-PRLB on chemoresistance. Recent studies showed that tumor microenvironment (TME) played significant role in proliferation, metastasis, and chemoresistance of cancer cells. And, modulation or disruption in TME could lead to a more effective management of cancer. Many IncRNAs were found to be involved in TME. Linc00092 is upregulated in response to the chemokine in ovarian cancer cells. LncRNA-MALAT1 promoted FGF2 protein secretion in tumor-associated macrophage, leading to inhibited inflammatory cytokine release, and thus promoting the proliferation and metastasis of thyroid cancer. Therefore, other functions of IncRNA-PRLB, such as regulation in immune effector cells, release of cancer immunoediting, macrophage polarization, and so on, would be investigated in future work. Thus, our present study identified IncRNA-PRLB as a potential prognostic marker and a therapeutic target for breast cancer.

To further investigate the mechanisms of IncRNA-PRLB, we first explored its location in breast cancer cells. Cell cytoplasm/nucleus fraction isolation assay identified that IncRNA-PRLB was mainly located in the cytoplasm. Then, ceRNA mechanism was first considered. Multiple studies have documented that IncRNAs harbor potential miRNA-responsive elements and function as competitive platforms for miRNAs in multiple types of cancer, thus reducing the repression of miRNAs. Through bioinformatic algorithms, we predicted a novel microRNA, miR-4766-5p, as a potential target of IncRNA-PRLB. Dual-luciferase reporter gene assay revealed the direct interaction between IncRNA-PRLB and miR-4766-5p, which was also proven by co-immunoprecipitation with the Ago2 protein in human embryonic kidney 293T (HEK293T) cells. We also found that changes in miR-4766-5p expression led to opposite changes in the expression of the miR-4766-5p target gene, SIRT1. On the other hand, overexpression of miR-4766-5p reduced IncRNA-PRLB expression, suggesting that IncRNA-PRLB and miR-4766-5p could form a reciprocal repression feedback loop. The direct binding of miR-4766-5p and 3′-UTR of SIRT1 was further validated by dual-luciferase reporter assay. In addition, our in vitro and in vivo systems revealed that the IncRNA-PRLB knockdown led to a decrease in the expression of SIRT1 and an increase in the expression of miR-4766-5p. Together, these data strongly supported the role of IncRNA-PRLB as a sponge, or ceRNA, for miR-4766-5p, and we firstly identified miR-4766-5p as a tumor suppressor in breast cancer.
Fig. 6 (See legend on next page.)
SIRTs are a family of NAD$^+$-dependent class III histone deacetylases43, 44, including seven human SIRTs with diverse subcellular locations and functions. SIRT1 is the most extensively studied member among SIRT family. The expression of SIRT1 is upregulated in multiple types of tumors, and is associated with tumor progression and resistance to cancer chemotherapy45, 46. Zhang et al.47 revealed that SIRT1 overexpression was associated with poor survival outcome in gastric cancer patients. Silencing SIRT1 suppressed non-small-cell lung cancer cell proliferation and dramatically suppressed tumor formation.48 SIRT1 was significantly upregulated in pancreatic cancer tissues and cell lines, and played a role in the regulation of pancreatic cancer cell proliferation and migration.49 Another study also showed that SIRT1 expression levels were significantly upregulated in breast cancer tissues, and SIRT1 overexpression eliminated the suppressive effects of the miR-22 overexpression on the malignant phenotype of MCF7 cells.50 Interestingly, some studies claimed that SIRT1 could inhibit tumor progression. SIRT1 overexpression inhibited human colon cancer cell proliferation51. Ectopic expression of SIRT1 in mesenchymal stem cells suppressed breast cancer growth52, while reduced SIRT1 levels in breast cancer cells led to increased metastasis through deacetylating Smad4 signaling53. According to previous studies, it remains controversial whether SIRT1 acts as an oncogene or tumor suppressor, and its specific functions may depend on diverse biological signaling. In addition, researches on SIRT1 in breast cancer were particularly confusing. Here, we demonstrated that SIRT1 knockdown could inhibit proliferation, metastasis, and chemoresistance in breast cancer cells, which was modulated by lncRNA-PRLB/miR-4766-5p network. Therefore, our study appears to support a tumor suppressor role for SIRT1 in breast cancer. Moreover, lncRNA-PRLB could not only increase SIRT1 at the mRNA level but also at the protein level. We further proved that lncRNA-PRLB overexpression could dramatically prolong the half-life of SIRT1 protein after adding the translation inhibitor cycloheximide, indicating the effect of lncRNA-PRLB on the protein stability of SIRT1.

In conclusion, the present study for the first time revealed that lncRNA-PRLB was upregulated in breast cancer tissues and cell lines, and higher levels of lncRNA-PRLB were associated with tumor progression and inversely correlated with prognosis. It was reasonable for us to conclude that lncRNA-PRLB promoted breast cancer cell proliferation, metastasis, and chemoresistance via miR-4766-5p-mediated regulation of SIRT1 signaling, although more clinical samples and further investigations of the exact roles of lncRNA-PRLB in other cancers were required. On the basis of these findings, the present study provided a better understanding of the lncRNA–miRNA feedback loop function in breast cancer progression. LncRNA-PRLB could be considered as a potential target for the breast cancer therapies in the future.

Materials and methods

Patients and samples

Tumor samples were obtained from breast cancer patients admitted to Qilu hospital from January 2004 to December 2011. The period of follow-up of all patients is 1–96 months, with a median of 43 months. For all participants in this study, written informed consent for the use of these clinical materials in research was obtained. This study was approved by the Ethical Committee of Shandong University.

Microarray analysis

LncRNA microarrays were used to profile lncRNA expression from two chemosensitive breast cancer tissues and two chemoresistant tissues. GeneChips were scanned by the Affymetrix® GeneChip Command Console. Quantile normalization and subsequent data processing were analyzed by Agilent Gene Spring Software 12.6 (Agilent Technologies, Santa Clara, CA, USA). A P value was calculated using the paired t test. When the lncRNA
expression level changed at least 1.5-fold with \( P < 0.05 \), the lncRNA expression was then considered significantly different.

**Cell lines and culture conditions**

All the cell lines were purchased from American Type Culture Collection (ATCC, Manassas, VA, USA) and were routinely maintained in Dulbecco’s modified Eagle’s medium/high glucose medium (Gibco-BRL, Rockville, IN, USA) with 10% fetal bovine serum, 100 U/mL penicillin, and 100 \( \mu \)g/mL streptomycin in a humidified incubator under the conditions of 5% \( \text{CO}_2 \) at 37 \( ^\circ \)C.

---

**LncRNA-PRLB promoted tumorigenesis, metastasis, and chemoresistance in vivo.** MDA-MB-231 cells were transfected with shPRLB or pSUPER and injected subcutaneously into nude mice. When the average tumor size reached approximately 100 mm\(^3\), 5-FU was administered through intraperitoneal injection at a dose of 50 mg/kg every other day for three doses in total. **a** Photographs illustrated tumors in xenografts. **b** Growth curve of xenograft tumors after the first administration of 5-FU. **c** LncRNA-PRLB knockdown combined with 5-FU treatment resulted in a dramatic decline of tumor weight. **d** Representative images of H&E and immunohistochemical staining of tumors. IHC revealed a downregulation of the proliferation index Ki-67 and SIRT1. **e** Representative images of lungs and hematoxylin and eosin (H&E) staining of lungs isolated from mice that received tail vein injection of MDA-MB-231 pcDNA3.1-PRLB cells and MDA-MB-231 pcDNA3.1 cells. Each group contains six mice. **f** The number of pulmonary metastatic nodules in the lung were counted and analyzed with Student’s t-test. *\( P < 0.05 \), **\( P < 0.01 \), and ***\( P < 0.001 \).
RNA extraction, reverse transcription, and qRT-PCR
Total RNA was extracted from cells or tissues using TRizol reagent (Invitrogen, Carlsbad, CA, USA). For miRNA, RNA was converted into cDNA using PrimeScript miRNA cDNA Synthesis Kit (TaKaRa, Shiga, Japan). PrimeScript reverse transcriptase (RT) Reagent Kit (TaKaRa, Shiga, Japan) was used to synthesize cDNA of IncRNA and mRNA. qRT-PCR was performed using a SYBR green PCR mix in Applied Biosystems 7900HT Real-Time PCR System. The primers (Sangon Biotech, Shanghai, China) used in this study were listed in Supplementary Table 5. β-Actin was used as an endogenous control for mRNA expression of each sample and small nuclear RNA U6 for the expression of microRNAs. Experiments were repeated three times to confirm the findings. Gene expression profiles were calculated using 2^−ΔΔCt method.

Psmid construction and transfection
For overexpression of IncRNA-PRLB, IncRNA-PRLB cDNA was cloned into the multiple cloning site of the pcDNA3.1 vector (Invitrogen, Carlsbad, CA, USA). Both the expression plasmid vector and the empty vector were used to transfect breast cancer cells using Lipofectamine 2000 (Invitrogen, MA, USA) to establish IncRNA-PRLB overexpression and control cell lines, screened with puromycin (2 μg/ml) for 4 weeks. LncRNA-PRLB knockdown cell lines were transfected with pSUPER or shPRLB. Transfection was performed with Lipofectamine 2000 (Invitrogen) according to the manufacturer’s instructions. All the mimics or siRNA were purchased from Applied Biological Materials (ABM, Canada).

MTT and in vitro chemosensitivity assay
Cells were cultured in 96-well plates in the culture medium. After incubation overnight, the medium was replaced with solutions containing different concentrations of 5-FU with the indicated concentration for 48 h or 30 μg/ml 5-FU followed by incubation for the indicated time. Afterwards, 20 μl of MTT (5 mg/ml in PBS) was added to each well and the cells were incubated for another 4 h at 37 °C. The supernatants were aspirated carefully and then 100 μl of dimethyl sulfoxide was added to each well. The absorbance values were read using a Microplate Reader (Bio-Rad, Hercules, CA, USA) at 570 nm after gently shaking of the plate for 10 min at room temperature.

Cell cycle assay
After 48 h of transfection, cells were trypsinized, and then washed with cold PBS twice. Then, the cell plates were suspended with 300 μl PBS, followed by the addition of 500 μl cell cycle staining buffer (MultiSciences (Lianke) Biotech Co., Ltd.). After 30 min incubation at room temperature, cells were sorted by FACS Calibur (BD Biosciences, Franklin Lakes, NJ, USA), and the profiles were analyzed by the ModFitLT V2.0 software (Becton Dickinson).

PE Annexin V apoptosis assay
PF/Annexin V Apoptosis Detection Kit (BD Biosciences, Franklin Lakes, NJ, USA) was used for apoptosis analysis following the manufacturer’s instruction. 5-FU of 30 μg/ml was used to induce apoptosis for 24 to 48 h. Cells were collected, washed twice with PBS, and gently resuspended in 500 μl binding buffer. After the addition of 5 μl Annexin V-FITC and 5 μl propidium iodide, the cells were incubated in the dark for 15 min at room temperature, followed by immediate flow cytometry analysis on a FACS Calibur (BD Biosciences, Franklin Lakes, NJ, USA).

TUNEL assay
5-FU of 30 μg/ml was used for treatment. TUNEL Apoptosis Assay was performed using the One Step TUNEL Apoptosis Assay Kit (Beyotime, Jiangsu, China) according to the guidelines. Apoptotic cells (red fluorescence) were imaged under a fluorescent microscopy.

WB analysis
Total cellular protein from each sample were separated by 10% sodium dodecyl sulfate-polyacrylamide gel electrophoresis and electroblotted onto a polyvinylidene fluoride membrane using a semidy blotting apparatus (Bio-Rad, Hercules, CA, USA). The membranes were blocked with 5% nonfat milk at room temperature for 1 h, followed by incubation with primary antibodies (Immuno-Way, Newark, DE, USA) overnight at 4 °C. After washing with TBST and incubation with the appropriate secondary antibodies, the protein bands were detected using the Pro-lighting HRP agent. Expression of β-actin was used as an endogenous loading control.

Migration and invasion assays
Migration and invasion assays were performed using the Transwell system (24-wells, 8-μm pore size with polycarbonate membrane; Corning Costar, Lowell, MA, USA). Cells (1 × 10^5 cells per well) were plated on the top side of polycarbonate Transwell filter coated (for invasion assays) or uncoated (for migration assays) with Matrigel in the top chamber. Cells were suspended in the medium without serum, and the medium supplemented with serum was used as a chemoattractant in the bottom chamber. The cells were incubated at 37 °C for 24 h. The noninvasive cells in the top chambers were removed with cotton swabs, whereas the migrated and invaded cells on the lower membrane surface were fixed in 100% methanol for 10 min, and then stained with 0.2% Giemsa and counted in three random fields using an Olympus light microscope.
Subcellular fractionation location
The separation of nuclear and cytosolic fractions was performed using the PARIS Kit (Life Technologies, Carlsbad, CA, USA) according to the manufacturer’s instructions.

Luciferase assay
LncRNA-PRLB with WT or MUT mir-4766-5p-binding sites were generated and fused to the luciferase reporter vector pmirGLO (Promega, Madison, WI, USA). The full-length WT 3′-UTR containing the predicted miR-4766-5p targeting site, and MUT 3′-UTR of SIRT1 were amplified and cloned into the pmirGLO vector. HEK293T cells were plated on a 96-well plate and co-transfected with luciferase plasmids and miR-4766-5p or control miRNA. After 48 h transfection, luciferase activity was measured with the dual-luciferase reporter assay system (Promega). Firefly luciferase activity was normalized against Renilla luciferase activity.

RIP assay
RIP experiments were performed using the Magna RIP RNA-Binding Protein Immunoprecipitation Kit (Millipore, Billerica, MA, USA) according to the manufacturer’s instructions. Antibody for RIP assays of AGO2 or control IgG was from Millipore. The co-precipitated RNAs were detected by qRT-PCR. The total RNAs were the input controls.

Tumor xenograft experiments
Stably transfected cells were harvested and resuspended in serum-free medium at a concentration of 1 × 10⁷ cells/0.2 ml, and injected subcutaneously into each flank of the 4–6-week-old nude female mice. When the average tumor size reached approximately 100 mm³, 5-FU was administered through intraperitoneal injection at a dose of 50 mg/kg every other day for three doses in total. Tumor size was monitored every 5 days, and mice were euthanized after 30 days. Both maximum (L) and minimum (W) length of the tumor were measured using a slide caliper, and the tumor volume was calculated as ½LW². To produce experimental lung metastasis, 5 × 10⁵ cells were injected into the lateral tail veins of female nude mice (six mice per group). After 4 weeks, all the mice were killed under anesthesia. The lungs were collected and fixed in 10% formalin and embedded in paraffin. H&E staining was performed on sections from embedded samples.

Immunohistochemical analysis
Tissue sections were dried at 60 °C for 1 h, and then dewaxed in xylene and rehydrated in a graded series of ethanol. Antigen retrieval was performed by microwave heating. Nonspecific antigens were blocked with 5% bovine serum albumin in the room temperature for 30 min. Each section was treated with Ki-67 rabbit polyclonal antibodies (1:100 solution) at 4 °C overnight. Each section was incubated with secondary antibody at 37 °C for 1 h, then stained with diaminobenzidine, and counterstained with hematoxylin. The representative areas were selected for images using an Olympus light microscope.

Statistical analysis
SPSS version 18.0 software was used for statistical analysis. Data are presented as the mean ± standard error of the mean (SEM) from at least three independent experiments. Two group comparisons were performed with a Student’s t test. Survival rates were calculated by Kaplan–Meier survival analysis. Cox proportional hazards model multivariate analyses were used to evaluated the influence of LncRNA-PRLB expression and clinicopathological features on overall survival. Differences with P < 0.05 were considered statistically significant.

Acknowledgements
This work was supported by National Natural Science Foundation of China (No. 81272903; No. 81672613), Key Research and Development Program of Shandong Province (No. 2016GGI2775), Shandong Science and Technology Development Plan (2016CYJ501A02) and Special Support Plan for National High Level Talents (“Ten Thousand Talents Program”) to Q.Y.

Author details
1Department of Breast Surgery, Qilu Hospital, Shandong University, 250012 Jinan, Shandong, China. 2Pathology Tissue Bank, Qilu Hospital, Shandong University, 250012 Jinan, Shandong, China. 3Department of Urology, Shandong Cancer Hospital affiliated to Shandong University, 250117 Jinan, Shandong, China

Author contributions
Y.R.L. and Q.F.Y. designed the experiments; Y.R.L., X.J.S., Y.M.L., Y.T.S., H.W.Z., Y.L., and Y.D. carried out most of the experiments; N.Z., B.C., W.J.Z., and L.J.W. collected samples; Y.R.L. and R.B.G. performed data analysis; Y.R.L. and R.B.G. prepared the figures and tables; Y.R.L. and Q.F.Y. wrote and revised the manuscript.

Conflict of interest
The authors declare that they have no conflict of interest.

Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information accompanies this paper at https://doi.org/10.1038/s41419-018-0582-1.

Received: 10 December 2017 Revised: 19 February 2018 Accepted: 5 April 2018
Published online: 11 May 2018

References
1. Stagli, J. M. et al. Long-term psychological benefits of cognitive-behavioral stress management for women with breast cancer: 11-year follow-up of a randomized controlled trial. Cancer 121, 1873–1881 (2015).
2. Fidler, I. J. The pathogenesis of cancer metastasis: the "seed and soil" hypothesis revisited. Nat. Rev. Cancer 3, 453–463 (2003).
3. Davuluri, G., Schiemann, W. P., Plow, E. F. & Sossey-Alaoui, K. Loss of WAVE3 sensitizes triple-negative breast cancers to chemotherapeutics by inhibiting the STAT-HIF-1alpha-mediated angiogenesis. *JAK-STAT* 3, e1009276 (2014).

4. Tanio, K. & Akiyama, N. Long non-coding RNAs in cancer progression. *Front. Genet.* 3, 219 (2012).

5. Wapienski, O. & Chang, H. Y. Long noncoding RNAs and human disease. *Trends Cell Biol.* 21, 354–361 (2011).

6. Ulltby, I. & Bartel, D. P. LncRNAs: genomics, evolution, and mechanisms. *Cell* 154, 26–46 (2013).

7. Demir, T. et al. The GENCODE v7 catalog of human long noncoding RNAs: analysis of their gene structure, evolution, and expression. *Genome Res.* 22, 1775–1789 (2012).

8. Kutter, C. et al. Rapid turnover of long noncoding RNAs and the evolution of gene expression. *PLoS Genet.* 8, e1002841 (2012).

9. Chakravarty, D. et al. The oestrogen receptor alpha-regulated lncRNA NEAT1 is a critical modulator of prostate cancer. *Nat. Commun.* 5, 3583 (2014).

10. Huang, M. D. et al. Long non-coding RNA ANRIL is upregulated in hepatocellular carcinoma and regulates cell apoptosis by epigenetic silencing of MTLF2. *J. Hematol. Oncol.* 8, 50 (2015).

11. Deng, H. P. et al. Long non-coding RNA HOTTIP promotes tumor growth and inhibits cell apoptosis in lung cancer. *Cell. Mol. Biol.* 61, 34–40 (2015).

12. Li, Z. et al. The long non-coding RNA HOTTIP promotes progression and gemcitabine resistance by regulating HOXA13 in pancreatic cancer. *J. Transl. Med.* 13, 84 (2015).

13. Fang, S. et al. Long noncoding RNA-HOTAIR affects chemoresistance by regulating HOXA1 methylation in small cell lung cancer cells. *Lab. Invest.* 96, 60–68 (2016).

14. Hong, Q. et al. LncRNA HOTAIR regulates HIF-1alpha/AKR signaling through inhibition of miR-217 in renal cell carcinoma. *Cell Death Dis.* 8, e2772 (2017).

15. Wang, W. et al. Serum HOTAIR as a novel diagnostic biomarker for esophageal squamous cell carcinoma. *Mol. Cancer* 16, 75 (2017).

16. Ozes, A. R. et al. NF-kappaB-HOTAIR axis links DNA damage response, chemoresistance and cellular senescence in ovarian cancer. *Oncogene* 35, 5350–5361 (2016).

17. Gutschner, T. et al. The noncoding RNA MALAT1 is a critical regulator of the metastasis phenotype of lung cancer cells. *Cancer Res.* 73, 1180–1189 (2013).

18. Yu, M. et al. Lnc00152 promotes malignant progression of glioma stem cells. *Cell Death Dis.* 6, e1009276 (2015).

19. Graham, L. D. et al. Colorectal neoplasia differentially expressed (CRNDE), a novel gene with elevated expression in colorectal adenomas and adenocarcinomas. *Genes Cancer* 2, 829–840 (2011).

20. Han, P. et al. The IncRNA CRNDE promotes colorectal cancer cell proliferation and chemoresistance via miR-181a-5p-mediated regulation of Wnt/beta-catenin signaling. *Mol. Cancer* 16, 9 (2017).

21. Gao, H. et al. Long noncoding RNA CRNDE functions as a competing endogenous RNA to promote metastasis and oxaliplatin resistance by sponging miR-136 in colorectal cancer. *Oncotarget* 10, 205–216 (2017).

22. Salmena, L., Poliseno, L., Tay, Y., Kats, L. & Pandolfi, P. P. A cellular hypothesis: the Rosetta Stone of a hidden RNA language? *Cell* 146, 353–358 (2011).

23. Cesana, M. et al. A long noncoding RNA controls muscle differentiation by functioning as a competing endogenous RNA. *Cell* 147, 358–369 (2011).

24. Wang, J. et al. CREB up-regulates long non-coding RNA HULC expression through interaction with microRNA-372 in liver cancer. *Nucleic Acids Res.* 38, 349–357 (2010).

25. Banfai, B. et al. Long noncoding RNAs are rarely translated in two human cell lines. *Genome Res.* 22, 1646–1657 (2012).

26. Li, Z. et al. The degradation of EZH2 mediated by IncRNA ANCR attenuated the invasion and metastasis of breast cancer. *Cell Death Differ.* 24, 59–71 (2017).

27. Pae, Z. et al. Down-regulation of IncRNA CASCA2 promotes cell proliferation and metastasis of bladder cancer by activation of the Wnt/beta-catenin signaling pathway. *Oncotarget* 8, 18145–18153 (2017).

28. Gu, P. et al. IncRNA HOXD-AS1 regulates proliferation and chemo-resistance of castration-resistant prostate cancer via recruiting WRN. *Mol. Ther.* 25, 1959–1973 (2017).